Synopsis: Windlas Biotech looks like a solid story on paper with expanding capacity and no net debt hanging over its head. Still, the stock has dropped more than 7% in the past year. Is Windlas Biotech quietly building a scalable growth engine the market hasn’t priced in yet?
Everyone loves chasing after the big-name pharma companies, which are the ones with celebrity doctors and flashy export numbers. But honestly, the real action might be happening behind the scenes. Think about those companies quietly making medicines for other brands, scaling up their factories, and catching the wave of global outsourcing.
That’s where real, steady growth can sneak up on you. In this article, we will look at one such company that fits this theme and might be a solid proxy to enter the pharmaceutical market.
With a market capitalisation of Rs 1,698 crore, the shares of Windlas Biotech Ltd closed at Rs 803.45 per share, up 0.8 from its previous day’s closing price of Rs 797.05 per share. In the last one year, the stock has declined by nearly 4 percent as compared to NIFTY 50’s positive return of 11 percent. It is essential to know the functioning of the pharmaceutical value chain before analysing Windlas Biotech.
Understanding the Pharma value chain
Every medicine follows a defined journey before reaching a patient. At firstly, it begins with manufacturing the Active Pharmaceutical Ingredient (API), which is the core chemical compound responsible for the therapeutic effect. For example, in a paracetamol tablet, paracetamol itself is the API. API manufacturers operate chemical plants and supply bulk drug ingredients to formulation companies. Their customers are other pharma manufacturers and not patients.
The second phase is formulation, during which the APIs are transformed into dosage forms in the form of tablets, capsules, syrups, or injections by blending them with excipients, compressing or filling them into dosage forms, and packaging them to be sold.
At this level, there are two business models that can be pursued by companies. One of them is the branded generics model, in which firms produce and sell drugs under their brand names, via physician networks, intermediaries, and pharmacies. It is a brand-driven and heavy marketing model. The second model is that of contract manufacturing, whereby a company produces medicines under the name of other pharma brands. This is the CDMO model, Contract Development and Manufacturing Organisation.
CDMO is not concerned with branding or promotion of doctors. In its place, it factors in product development, regulatory adherence, formulation knowledge, and large-scale production capability. It has pharma companies as its customers who outsource production and do not direct patients. Windlas Biotech has been working mostly in this CDMO space as a means of becoming an axial manufacturing partner instead of an antipodal branded player.
Windlas Biotech Business Overview
Windlas Biotech was established in the year 2001, and since then, they have not only expanded to five formulation plants in Dehradun, Uttarakhand, but have also commissioned a new injectables plant. The business can produce up to 8.5 billion tablets and capsules per year, 54 million pouch & sachets and 61 million liquid bottles, and currently injectable preparations. It has over 177 employees who are concerned with quality control, which is an indication of its compliance operating model.
The company has three segments, which include CDMO services, domestic trade generics and institutional sales, and exports. In the first nine months of FY26 (9M FY26), the company derived 73 percent of its revenue from the CDMO segment, followed by 23 percent from Trade Generics & Institutional and the remaining 4 percent from Exports.
CDMO revenues in FY25 were about Rs 555 crore, and they increased at an annual rate (CAGR) of about 14 percent since FY20. Windlas has a customer base of 757 customers, which has also grown by a staggering 40 percent CAGR since FY20, and produces more than 5,500 brand formulations. Notably, the concentration among customers is now lower with the top 10 clients having 34 percent of the revenue as compared to 57 percent in FY20. This diversification minimises the risk of dependency and stabilises cash flows.
The overall CDMO sector is growing. Approximately 35-40 percent of the pharmaceutical output in India was outsourced in FY23, and this is likely to rise to 40-45 percent by FY 28. In other words, nearly half of all drug manufacturing in India could be done by contract manufacturers in the coming years, which signals plenty of business opportunities for a company like Windlas.
Indian pharma contract manufacturing business (CDMO) is expected to experience a CAGR of 12-14 percent and reach the mark of Rs 2,400-2,500 billion by FY28, which itself presents a massive opportunity. The shape of the market in CDMO is expected to reach 40-45 billion across the globe by 2027. This organisational change of outsourcing is serving to push Windlas towards a long-term growth curve.
The Trade Generics and Institutional Opportunity.
The second growth engine is domestic trade generics & institutional business of Windlas, which means the company sells generic medicines under its own brand names within India. Trade generics are also sold directly to stockists and pharmacists, unlike branded generics, which rely extensively on the services of medical representatives and doctor prescriptions.
Prices of these medicines are usually 15-25 percent less than branded versions and have a 60-90 percent margin with the chemists. This model cuts down on the cost of marketing and enables infiltration of more into the tier-2, tier-3 and rural markets.
Trade Generics & Institutional revenues in FY25 were about Rs 172 crore, and they increased at a staggering annual rate (CAGR) of about 42 percent since FY20. Today, Windlas sells approximately 400 products in 29 states with the help of 1,095 stockists. The company has an AAA strategy, which is Accessible, Affordable and Authentic, and it focuses on underserved populations.
The Indian trade generics market is approximated at FY23 as Rs 9,100 crore; and it is expected that it will reach Rs 14,000-15,000 crore by FY28, growing at a robust CAGR of 9.5-10 percent.
Government programs such as Jan Aushadhi which have more than 24,000 outlets throughout the country are boosting the use of low-cost generics. With affordability of healthcare emerging as a policy agenda, such a segment presents good structural tailwinds.
Financials
The revenue from operations for Windlas Biotech stands at Rs 233 crores in Q3 FY26 compared to Q3 FY25 revenue of Rs 195 crores, up by 20 per cent YoY. Additionally, on a QoQ basis, it reported a slight growth of 5 percent from Rs 222 crore.
Also, EBITDA stood at Rs 24 crore in Q3 FY26, a decline of 4 percent as compared to Rs 25 crore in Q3 FY25. Additionally, on a QoQ basis, it reported a decline of 17 percent from Rs 29 crore. Also, coming to the margins front, EBITDA margins declined by 300 bps YoY, reaching 10 percent in Q3 FY26.
Coming down to its profitability, the company’s net profit stood at Rs 15 crore in Q3 FY26, a decline of 4 percent as compared to Rs 16 crore in Q3 FY25. Additionally, on a QoQ basis, it reported a decline of 17 percent from Rs 18 crore.
Gross margins in Q3 FY26 increased by about 40 basis points as compared to the previous year, and the EBITDA margin without ESOP costs was 13.6 percent compared to 12.9 percent the previous year.
Windlas has a good balance sheet, and the company does not have net debt, but its liquidity measures around Rs 237 crore as of H1FY26. H1FY26 operating cash flow was at Rs 56 crore. The injection capital of injectables and Plant 6 are being financed with 100 percent internal accruals, which minimises risks of financial obligations and gives it the flexibility of possible acquisitions.
Capacity Expansion, Injectables and Operating Leverage
One of the significant sections of the growth thesis developed by Windlas is the capacity expansion. Recently, the company entered into a contract to have an injectables plant with capex of about Rs 72 crore. The maximum annual revenue that this plant is meant to produce is 100 crore at maximum utilisation. The management has quoted that at steady state, injectable EBITDA margins can be 18-21 percent as opposed to lower current margins owing to ramp-up expenditures.
Also, Windlas is increasing oral solid dosage capacity by plant 6, projected to add 25 percent capacity enhancement to increase yearly revenue potential of upto Rs 1,100 crore. The level of current usage of oral solid capacity is approximately 65 percent, which means that there is a large headroom. With an increase in utilisation, the fixed costs like depreciation and plant overheads will be absorbed in bigger volumes, leading toan increase in operating leverage.
Exports and Optionality
Exports made about Rs 29 crore in the first 9 months of FY26, which is approximately 4 percent of the revenue, but this segment is growing at a 25 percent CAGR since FY20. Windlas has more than 80 products exported to the Asian and African emerging markets. Although the firm is yet to have an international presence in more regulated markets such as the US or EU, it is submitting regulatory dossiers with an aim of growing its presence in international markets.
About 50 percent of pharmaceutical production is exportedto other countries, and India accounts for about 3.5% of global drugs and medicines exports in value terms. Formulation export is expected to increase by 6-8 percent per annum. Although exports constitute a minor part of Windlas ‘ business currently, it is a form of long-term optionality, especially with injectables creating new opportunities in the world
Financial Forecast and Appraisals Framework.
The management has revealed that with full utilisation of the current assets, Windlas has the potential to generate approximately Rs 1,100 crore of revenue annually. Incremental contribution through injectables and Plant 6 would bring the capacity utilisation to optimum levels by FY27. Operating leverage would be of significant value in increasing profitability, assuming the gradual improvement in the EBITDA margins to 14.5-15 percent by FY28.
Key risks
Windlas relies heavily on a few major CDMO clients, so losing even one, renegotiating contracts, or just seeing slower demand from them can significantly impact revenue and margins.
The pharmaceutical industry is also challenging, being highly regulated, so any misstep, like a quality lapse, a failed inspection, or a product recall, can disrupt operations and damage the company’s reputation. As Windlas expands into injectables and begins exporting, the compliance and regulatory challenges only increase.
Their future growth depends on successfully launching new projects like injectables and getting Plant 6 operational without issues. If regulatory approvals are delayed, customers are slow to sign up, or if the new capacity isn’t utilised enough, fixed costs could start eroding margins. On top of all this, competition in both CDMO and trade generics is intense. Government price controls and strict tender requirements add even more pressure on pricing and profitability—even when sales volumes are rising.
In summary, Windlas Biotech is a backend play of the picks and shovels on the pharmaceutical development story of India. It does not compete in branded segments that are highly marketed, but operates as a manufacturing backbone through its CDMO business, with growth being overlaid with trade generics, institutional sales, injectables, and gradual expansion of its export business.
The company has 73 percent of revenue in its CDMO, 23 percent in high-growth trade generics, and expanding capacity, rising margins, and a balance sheet free of debt; thus is set to take advantage of the pattern of structural outsourcing and domestic healthcare growth.
However, the most important variables to monitor in 2-3 years comprise the capacity utilisation rates, injectable ramp-up, customer diversification, trade generics expansion pace, margin trend to a 15 percent span and disciplined capital allocation. With a steady execution, Windlas can achieve meaningful compounding in earnings since the operating leverage takes effect.
It is not a facade pharma brand narrative. It is a manufacturing capacity narrative supported by numbers, scale and structural tailwinds and that is what makes it interesting.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Windlas Biotech: How this company Is Powering Growth Through CDMO, Generics and more appeared first on Trade Brains.